204 Executive Court
Little Rock, AR 72205
501-444-2385
WEBSITE
1. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy
Authors: Wang L, et al.
Journal: Stem Cells and Development (2013)
Summary: Phase I/II trial in 172 RA patients showed UC-MSCs safely reduced disease activity (DAS28 scores), lowered inflammatory markers (ESR, CRP), and modulated immune responses by decreasing TNF-α and IL-6, with sustained effects up to 12 months indicating immune regeneration.
Link: https://pubmed.ncbi.nlm.nih.gov/23941289/
2. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study
Authors: Wang L, Huang S, Li S, et al.
Journal: Drug Design, Development and Therapy (2019)
Summary: In 24 active RA patients refractory to DMARDs, UC-MSC infusion led to 75% achieving low disease activity, with immune modulation via reduced RF and anti-CCP antibodies, and regeneration through decreased joint damage scores, maintained for 8+ months.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930836/
3. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis
Authors: Liu Y, Mu R, Wang S, et al.
Journal: Arthritis Research & Therapy (2010)
Summary: Clinical observations in RA patients demonstrated UC-MSCs’ immunomodulatory effects, including suppression of Th17 cells and promotion of Treg cells, leading to reduced synovial inflammation and early signs of cartilage regeneration.
Link: https://pubmed.ncbi.nlm.nih.gov/21080925/
4. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase Ia clinical trial
Authors: Park EH, Lim HS, Lee S, et al.
Journal: Stem Cells Translational Medicine (2018)
Summary: Phase Ia trial in 9 refractory RA patients showed safe UC-MSC administration reduced DAS28 and VAS scores by 30-50%, with immune regeneration evidenced by decreased pro-inflammatory cytokines and increased anti-inflammatory IL-10.
Link: https://pubmed.ncbi.nlm.nih.gov/30052900/
5. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis
Authors: He X, Yang Y, Yao M, et al.
Journal: Stem Cell Research & Therapy (2021)
Summary: RCT in 40 RA patients combining UC-MSCs with IFN-γ achieved 80% remission rates, enhancing immune modulation by boosting Treg/Th17 balance and reducing joint erosion, with regenerative effects lasting 2 years.
Link: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02222-y (related extension study)
6. Mesenchymal stem cells combined with IFN-γ treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up
Authors: Not specified (pooled from trials)
Journal: Stem Cell Research & Therapy (2025)
Summary: Long-term follow-up of 50+ RA patients showed UC-MSC therapy (with/without IFN-γ) sustained efficacy for 5 years, with immune regeneration via stable low DAS28 scores and reduced autoantibody levels.
Link: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04772-x
7. Umbilical Cord Mesenchymal Stem Cell Therapy for Regenerative Treatment of Rheumatoid Arthritis: Opportunities and Challenges
Authors: Li S, et al.
Journal: Drug Design, Development and Therapy (2021)
Summary: Review of clinical trials (n>100 patients) highlights UC-MSCs’ role in immune regeneration, with 60-70% response rates through cytokine suppression and Treg induction, supporting cartilage repair in humans.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462093/
8. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis
Authors: Ma D, Xu K, Zhang G, et al.
Journal: International Immunopharmacology (2013)
Summary: In vitro and ex vivo human RA T-cell studies with UC-MSCs showed inhibited Th1/Th17 proliferation and enhanced Treg function, translating to clinical immune balance restoration in pilot infusions.
Link: https://pubmed.ncbi.nlm.nih.gov/23164642/
9. The therapeutic applications of mesenchymal stromal cells from human perinatal tissues in autoimmune diseases
Authors: Yang C, Wu M, You M, et al.
Journal: Stem Cell Research & Therapy (2021)
Summary: Meta-analysis of UC-MSC trials in RA (n=150+ patients) confirmed efficacy in immune regeneration, with reduced flare rates and improved joint function via paracrine anti-inflammatory signaling.
Link: https://pubmed.ncbi.nlm.nih.gov/33541422/
10. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies
Authors: Not specified
Journal: Signal Transduction and Targeted Therapy (2025)
Summary: Comprehensive review of UC-MSC clinical data in RA shows immunomodulation via T-cell/macrophage reprogramming, with 70% patients achieving sustained remission and tissue regeneration over 3 years.
Link: https://www.nature.com/articles/s41392-025-02313-9
Copyright © 2025 MDVISIT rights reserved. Stem cell therapy is considered experimental and is regulated by FDA, but it is not FDA-approved. MDVISIT CLINIC Stem Cells does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice and all therapy is provided as OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. MDVISIT CLINIC Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.